11 Oct 2016
Data published in the New England Journal of Medicine has sparked discussion at the European Society for Medical Oncology Congress meeting. The study showed that the addition of a CDK 4/6 inhibitor, ribociclib, slowed disease progression of ER-positive breast cancer in post-menopausal women.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024